InxMed is a clinical-stage biotech firm founded at the end of 2018. The company is committed to developing novel therapies that target the stroma microenvironment as well as solid tumor resistance and metastasis, with a focus on anti-PD-1/PD-L1 treatment drug resistance. InxMed commits to becoming a global leader in revolutionary cancer therapies by establishing an efficient engine for clinical translational science and a proof of concept platform fueled by an in-depth understanding of disease biology.